Biosimilars: Real World Considerations For Pharmacists
Recorded on November 7, 2019
Sponsored by Amgen
Biosimilars are projected to lower health care costs and deliver more therapeutic options for physicians and patients. This presentation provides an overview of key pharmacist-specific considerations for biosimilars, including details of the approval process, considerations for appropriate use, and practices that mitigate inadvertent substitution and encourage accurate adverse event reporting. The development and approval process for biosimilars will be described in detail, including the concept of the totality of evidence and the individual data components. The presentation will also highlight the state of interchangeability in the United States, including a summary of its statutory definition, applicability to medical practice, implications for pharmacy substitution, and role in the uptake of biosimilars.
Leah Christl, PhD
Executive Director, Global Regulatory and R&D Policy
JAPAC Lead and Global Biosimilars
This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.